CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2013-04-23): Bristol-Myers oral HCV regimen looks competitive in phase II trial

Drug & Device Development

Bristol-Myers oral HCV regimen looks competitive in phase II trial

Last Updated: 2013-04-23 11:40:29 -0400 (Reuters Health)

(Reuters) - A combination of three experimental Bristol-Myers Squibb drugs appeared to be highly effective against the hepatitis C virus (HCV), according to data from a mid-stage clinical trial, keeping the company in the race for developing an all-oral treatment regimen for the disease.

The treatment achieved cure rates as high as 94% when given for either 12 weeks or 24 weeks, according to results of the small study. Data from the study will be presented this week at the European Association for the Study of the Liver (EASL) meeting in Amsterdam.

The drugs were the NS5A inhibitor daclatasvir, the protease inhibitor asunaprevir, and the non-nucleoside polymerase inhibitor BMS-791325 ('325). The three direct acting antiviral drugs each attack different targets needed for replication of the hepatitis virus.

Current treatment regimens for the disease still include the older, difficult-to-tolerate drugs interferon and ribavirin and are typically taken for either 24 weeks or 48 weeks. When used with newer drugs, they have cure rates as high as about 80%.

The multi-pronged study included 66 patients with the most common and difficult to treat genotype 1 form of the disease who had not previously been treated.

With the lower of two doses of '325 (75 vs 150 mg), the sustained virologic response 12 weeks after completing treatment (SVR 12) was 94%, and that was essentially maintained through 24 weeks. Patients in whom the virus is undetectable 24 weeks after completing treatment (SVR 24) are considered to be cured.

If data was excluded from the few patients who either missed a planned doctor visit and could not be tested or withdrew consent to participate, then all 28 patients in the lower dose arms of the trial were cured, Bristol-Myers said.

"It looks overall very promising," Dr. Eric Lawitz, one of the investigators who worked on the trial, said in a telephone interview from Amsterdam. "Anytime we can hit 90 percent SVR, we're very interested."

There was less available data ready in time for the EASL meeting from patients who got the 150 mg dose of '325, but that dose appeared to be a bit less promising than the lower dose. The SVR 12 rate for those who received 12 weeks of treatment was 89%. But there was one patient who had viral breakthrough after an initial response, and one patient who relapsed after completing treatment. There was also one viral breakthrough reported in the 24-week treatment group.

There were no patient discontinuations due to intolerance to the drugs or adverse events and no serious elevations in liver enzymes reported, the company said.

Two serious adverse events were reported. One patient suffered from kidney stones, which was deemed unrelated to the Bristol-Myers drugs by researchers, and one case of cerebral vasoconstriction in a patient taking interferon and ribavirin following viral breakthrough.

The most commonly reported side effects were headache, diarrhea, muscle weakness and nausea, the company said.

"There hasn't been any safety signal that has been concerning from what's been reported to date," said Dr. Lawitz, medical director of the Texas Liver Institute in San Antonio. He added that much larger studies with more diverse patient populations, such as those with cirrhosis, must be conducted to confirm the findings.

Several companies are developing hepatitis C regimens that do not include interferon while also pursuing much shorter treatment durations.

Gilead Sciences Inc and Abbvie Inc are widely seen as ahead of the pack with treatments that could reach the market as soon as next year. But those will likely, at least initially, include ribavirin, which many patients also have difficulty tolerating.

"The speed of drug development is moving quicker than any of us would have thought and the potency of these regimens with high (cures) is very good for the field and for patients," Dr. Lawitz said.

Bristol-Myers said it expects to begin Phase III testing of its combination by late 2013

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.